{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Showing 1 - 3 of 3 results
Status:
US Previously Marketed
Source:
DYNACAINE W/EPINEPH PYRROCAINE by GRAHAM CHEM
(1962)
Source URL:
First approved in 1962
Source:
DYNACAINE W/EPINEPH PYRROCAINE by GRAHAM CHEM
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Pyrrocaine is the amide local anesthetics. It is metabolized to 2,6-xylidine. It was used mainly as an infiltration and nerve block dental anesthetic in the 1960s and favored due to its rapid onset. The potency of pyrrocaine equals that of lidocaine in both sensory and motor nerve blocking. Pyrrocaine provided to be somewhat less toxic than lidocaine. No methemoglobinemia was clinically observed. It has been classified as unsafe for use in acute porphyria. There is no evidence that it is currently used commercially.
Status:
Possibly Marketed Outside US
Source:
NCT00856817: Phase 4 Interventional Terminated Atherosclerotic Cardiovascular Disease
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Heme arginate (or haem arginate, brand name NORMOSANG) has been used to treat acute porphyrias. NORMOSANG successful uses in Europe and South Africa, but it has not been approved for use in the United States. Heme arginate consists of haem complexed with the amino acid arginine. This forms a stable compound. Haem arginate works by replenishing haem stores within the body. By negative feedback, haem arginate inhibits the initial rate-limiting enzyme of the haem synthetic pathway, ALA synthase (Delta-aminolevulinic acid dehydratase). The most frequent complication is phlebitis at the site of infusion. This can be reduced by giving the infusion of haem arginate in a protein buffer such as stabilized human serum or human serum albumin. In addition, there were studies, which revealed, that heme arginate induced beneficial effects in some myelodysplastic syndrome (MDS) patients and had very few side effects. In addition was shown, that heme arginate could be useful in the treatment of thalassemia intermedia.
Status:
US Previously Marketed
Source:
DYNACAINE W/EPINEPH PYRROCAINE by GRAHAM CHEM
(1962)
Source URL:
First approved in 1962
Source:
DYNACAINE W/EPINEPH PYRROCAINE by GRAHAM CHEM
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Pyrrocaine is the amide local anesthetics. It is metabolized to 2,6-xylidine. It was used mainly as an infiltration and nerve block dental anesthetic in the 1960s and favored due to its rapid onset. The potency of pyrrocaine equals that of lidocaine in both sensory and motor nerve blocking. Pyrrocaine provided to be somewhat less toxic than lidocaine. No methemoglobinemia was clinically observed. It has been classified as unsafe for use in acute porphyria. There is no evidence that it is currently used commercially.
